November 30, 2018
5 Things to Know for NOVEMBER 2018
We are now entering the end of the year push. . . .
- Precision BioSciences (Derek Jantz & James Smith, School of Medicine) received FDA authorization to initiate clinical study of their gene edited cancer immunotherapy. The FDA has accepted the application for PBCAR0191, an allogeneic anti-CD19 CAR T therapy for B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma (NHL). PBCAR0191 is positioned to be the first gene-edited allogeneic CAR T product candidate in human clinical trials for NHL.
- Our 2nd Annual Invented at Duke celebration was a huge success with nearly 500 people in attendance, around 150 of those were faculty and staff. If you missed the event, you can see photos here. (and of course we hope to see you next year!)
- Phitonex (Alvin Lebeck) a Duke Trinity spin-out developing the next generation of fluorescent labels and instrumentation to advance the fight against disease, has raised $175,000 to move forward with their extraordinarily bright labels that are able span the entire visible spectrum.
- Acclivity Health Solutions, a healthcare technology company based in Florida, announced the acquisition of assets from Duke start-up Prepped Health (Jon Nicolla, DCI & Arif Kamal, School of Medicine). Prepped is a mobile application that helps patients with serious illness better prepare for their journey down a difficult and confusing road.
- School of Medicine start-up Tellus Therapeutics was selected as the top early stage company at the Southeast BIO conference this year. The company is developing therapeutics based on neonatalogist Eric Benner’s groundbreaking research on treating brain damage in newborns. Interestingly, a number of other Duke related companies received awards at the event including Locus BioSciences, Humacyte, and Precision Biosciences.